Flamel Technologies, Inc

Latest News

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

MedusaŽ

A Versatile Nano Carrier for the Delivery of Native Proteins

MedusaŽ, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here

"Novel Sustained Release Formulation of IL-2 Improves Pharmacokinetics Performance
and Demonstrates Potent Activation of Immunological Cell Line" click here

MicropumpŽ Technologies

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (MicropumpŽ I) or both delayed and extended (MicropumpŽ II) delivery of small molecule drugs.

more info

Flamel Technologies has invented two innovative polymer-based technologies:

• MicropumpŽ for the delivery of small molecule drugs, including pediatric and geriatric uses.

• MedusaŽ for the delivery of native protein drugs. Flamel provides tailored solutions to the industry for optimized controlled-released delivery of drugs.

• The Company turns already-marketed or new drugs into more effective and safer medicines.

• Well advanced and rich products pipeline: Genvir™, Metformin XL, FT-105, IFN alpha-2b XL, IL-2, hGH and EPO.

Research and Development Team

The Company has assembled a strong team of researchers expert in polymer science and biochemistry, including more than 35 Ph.D.s.

Flamel is helped in its innovative research and development work by two world renown scientists: Jean-Marie Lehn (Nobel Laureate in Chemistry in 1987) and Professor Christian Trepo, a world renowned expert in liver diseases.

Manufacturing Facility

The Company owns a 60,000-square foot pharmaceutical production facility located in Pessac, France.

The Pessac facility and its operation are approved by the European drug agencies and are in substantial compliance with "Good Manufacturing Practice" ("cGMP"). The facility provides Flamel with the capability to manufacture its cGMP-grade pharmaceutical drugs for clinical trials utilizing its MicropumpŽ or MedusaŽ technologies.